GT Biopharma Statistics

Total Valuation

GT Biopharma has a market cap or net worth of $5.30 million. The enterprise value is $922,069.

Market Cap	5.30M
Enterprise Value	922,069

Important Dates

The next estimated earnings date is Wednesday, May 14, 2025, after market close.

Earnings Date	May 14, 2025
Ex-Dividend Date	n/a

Share Statistics

GT Biopharma has 2.23 million shares outstanding. The number of shares has increased by 40.79% in one year.

Current Share Class	2.23M
Shares Outstanding	2.23M
Shares Change (YoY)	+40.79%
Shares Change (QoQ)	+1.04%
Owned by Insiders (%)	17.81%
Owned by Institutions (%)	65.23%
Float	1.62M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	-2.92
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.72

Current Ratio	0.72
Quick Ratio	0.67
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -453.39% and return on invested capital (ROIC) is -306.19%.

Return on Equity (ROE)	-453.39%
Return on Assets (ROA)	-97.90%
Return on Invested Capital (ROIC)	-306.19%
Return on Capital Employed (ROCE)	860.12%
Revenue Per Employee	n/a
Profits Per Employee	-$13.16M
Employee Count	1
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -46.50% in the last 52 weeks. The beta is 1.25, so GT Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.25
52-Week Price Change	-46.50%
50-Day Moving Average	2.29
200-Day Moving Average	2.51
Relative Strength Index (RSI)	50.43
Average Volume (20 Days)	36,118

Short Selling Information

The latest short interest is 94,195, so 4.22% of the outstanding shares have been sold short.

Short Interest	94,195
Short Previous Month	250,247
Short % of Shares Out	4.22%
Short % of Float	5.83%
Short Ratio (days to cover)	0.71

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-14.36M
Pretax Income	-9.64M
Net Income	-13.16M
EBITDA	n/a
EBIT	-14.36M
Earnings Per Share (EPS)	-$6.94

Full Income Statement

Balance Sheet

The company has $3.95 million in cash and n/a in debt, giving a net cash position of $3.95 million or $1.77 per share.

Cash & Cash Equivalents	3.95M
Total Debt	n/a
Net Cash	3.95M
Net Cash Per Share	$1.77
Equity (Book Value)	-1.67M
Book Value Per Share	-0.75
Working Capital	-1.67M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-12.90M
Capital Expenditures	n/a
Free Cash Flow	-12.90M
FCF Per Share	-$5.78

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

GT Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-40.79%
Shareholder Yield	-40.79%
Earnings Yield	-270.10%
FCF Yield	-264.80%

Analyst Forecast

The average price target for GT Biopharma is $11.00, which is 364.14% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.00
Price Target Difference	364.14%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on February 5, 2024. It was a reverse split with a ratio of 0.0333333:1.

Last Split Date	Feb 5, 2024
Split Type	Reverse
Split Ratio	0.0333333:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1